Published in Oncol Lett on September 06, 2013
Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.85
Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial. Eur Radiol (2015) 0.83
Prognostic factors for long term survival in patients with advanced non-small cell lung cancer. Ann Transl Med (2016) 0.78
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer (2015) 0.76
Early treatment with metformin induces resistance against tumor growth in adult rats. Cancer Biol Ther (2015) 0.75
Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Mol Clin Oncol (2017) 0.75
Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults. PLoS One (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
The new World Health Organization classification of lung tumours. Eur Respir J (2001) 6.91
The new lung cancer staging system. Chest (2009) 6.30
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol (2007) 3.75
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst (1999) 3.24
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol (2006) 2.85
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol (1994) 2.66
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol (2007) 2.57
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 2.19
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst (2002) 1.78
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol (1986) 1.76
Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer (1998) 1.76
Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res (1993) 1.61
The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol (2003) 1.58
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol (2010) 1.53
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. J Clin Oncol (2007) 1.50
Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer (2003) 1.45
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol (2005) 1.27
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
Geriatric oncology: challenges for the new century. Eur J Cancer (2000) 1.13
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol (2009) 1.12
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer (2003) 1.05
Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol (1994) 1.04
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer (2001) 1.02
[Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer]. Rev Mal Respir (2006) 0.98
Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control (2001) 0.95
Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 0.94
Non-small cell lung cancer in the elderly. Oncologist (2004) 0.87
[Epidemiological novelties in lung cancer]. Rev Mal Respir (2011) 0.82
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol (2010) 0.81
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol (2014) 0.97
Clinical and prognostic significance of coagulation assays in lung cancer. Respir Med (2012) 0.93
The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med (2012) 0.89
Primary Burkitt's Lymphoma Presenting as a Rapidly Growing Thyroid Mass. Case Rep Oncol (2012) 0.88
High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer. Tumour Biol (2014) 0.88
Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumour Biol (2014) 0.88
Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer. Int J Gynecol Cancer (2013) 0.87
Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology (2012) 0.86
Coagulation tests show significant differences in patients with breast cancer. Tumour Biol (2014) 0.84
Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer. Tumour Biol (2014) 0.82
Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma. J Gastrointest Cancer (2013) 0.82
Clinical and prognostic significance of coagulation assays in melanoma. Melanoma Res (2012) 0.82
Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumour Biol (2013) 0.82
Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumour Biol (2014) 0.82
Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol (2013) 0.81
Clinical significance of serum fibronectin and vitronectin levels in melanoma patients. Melanoma Res (2014) 0.80
Robotic mitral valve replacement for severe rheumatic mitral disease: perioperative technique, outcomes, and early results. Innovations (Phila) (2014) 0.80
Clinical and prognostic significance of coagulation assays in gastric cancer. J Gastrointest Cancer (2013) 0.80
Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev (2013) 0.80
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Medicine (Baltimore) (2016) 0.80
Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer. Tumour Biol (2013) 0.79
Serum M65 as a biomarker for metastatic renal cell carcinoma. Clin Genitourin Cancer (2013) 0.78
Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Tumour Biol (2013) 0.78
Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol (2013) 0.78
A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemother Pharmacol (2013) 0.77
Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J (2013) 0.77
Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients. Tumour Biol (2013) 0.76
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine (Baltimore) (2015) 0.76
Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Med Oncol (2012) 0.76
Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer. Tumour Biol (2014) 0.76
Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment. Medicine (Baltimore) (2015) 0.75
Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. Bosn J Basic Med Sci (2016) 0.75
Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. Cancer Chemother Pharmacol (2014) 0.75
Clinical significance of serum M30 and M65 levels in melanoma. Melanoma Res (2013) 0.75
Tongue metastasis of melanoma. J Cancer Res Ther (2015) 0.75
Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. Cancer Chemother Pharmacol (2015) 0.75
Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma. Tumour Biol (2014) 0.75
Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients Asian Pac J Cancer Prev (2017) 0.75
Combination of capecitabine and phenytoin may cause phenytoin intoxication: a case report. Am J Ther (2015) 0.75
Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer. Tumori (2013) 0.75
Recurrent gastric cancer presenting with both scrotal and facial skin metastases: a case report. J Gastrointest Cancer (2014) 0.75
Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy. Tumour Biol (2014) 0.75
Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature. Onkologie (2011) 0.75
Clinical significance of serum interleukin-17 levels in colorectal cancer patients. J BUON (2016) 0.75
Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer. Mol Cell Biochem (2014) 0.75